MABE144 Display Image

Anti-Ago3; clone 4B1-F6

Code: MABE144 D2-231

Application

Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in HeLa cells. (Azuma-Mukai, A., et al. (2008). Proc Natl Acad Sci. USA. ...


read more

Your Price
£328.00 EACH
£393.60 inc. VAT

Application

Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in HeLa cells. (Azuma-Mukai, A., et al. (2008). Proc Natl Acad Sci. USA. 105(23):7964-7969.)

Anti-Ago3 Antibody, clone 4B1-F6 is a Mouse Monoclonal Antibody for detection of Ago3 also known as eIF-2C 3, eIF2C 3, FLJ12765, MGC86946 & has been validated in ICC & IP.

General description

Eukaryotic translation initiation factor 2C 3, Ago3, belongs to the argonaute family and contains 1 PAZ and 1 Piwi domain. r>Ago3 is indicated to play a role in the RNA interference (RNAi) pathway, which is important for heterochromatin formation and accurate chromosome segregation. Unlike Ago1 and Ago2, Ago3 and AG04 do not possess the ability to dissociate miRNA duplexes in a minimal in vitro system. Re-introduction of any Ago variant into embyronic (ES) cells deficient for expression of all four Ago variants will rescue miRNA silencing defects and reduce apoptosis.

Immunogen

Recombinant protein corresponding to human Ago3.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Format: Purified

Quality

Evaluated by Immunocytochemistry in HeLa cells.

Immunocytochemistry Analysis: A 1:500 dilution of this antibody detected Ago3 in HeLa cells.

Target description

96 kDa calculated.

antibody formpurified immunoglobulin
antibody product typeprimary antibodies
biological sourcemouse
clone4B1-F6, monoclonal
Gene Informationhuman ... AGO3(192669)
isotypeIgG2aκ
NCBI accession no.NP_079128
Quality Level100
shipped inwet ice
species reactivityhuman
technique(s)immunocytochemistry: suitable, immunoprecipitation (IP): suitable
UniProt accession no.Q9H9G7
This product has met the following criteria: